AtheroGenics' AGI-1067 Pivotal Data Expected In Late Q1
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm believes a low event rate in the Phase III ARISE trial could signal a therapeutic effect of the atherosclerosis candidate, in development with AstraZeneca.
You may also be interested in...
AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout
Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
AtheroGenics To Lay Off Half Its Workforce On Heels Of ARISE Failure, AstraZeneca Pullout
Initiative will free up funds needed to file NDA on AGI-1067 without former partner AstraZeneca.
AstraZeneca Halts NXY-059 Development Following SAINT II Stroke Results
Firm returns the neuroprotectant to partner Renovis after pivotal trial in acute ischemic stroke fails to show statistical significance.